Fig. 1From: Engineering strategies for customizing extracellular vesicle uptake in a therapeutic contextSchematic diagram that represents EV engineering for cancer therapy in clinical application. A Activation of immunomodulatory cells (including Treg) and inhibition of cytotoxic cells (including NK cells) by cancer cell EVs in order to suppress immune response and lead to metastasis. B Treatment of cancer cell EV to cease EV uptake by immune cells, in order to activate immune response and inhibit metastasis. C Loading chemotherapy drugs into EV and engineering EV uptake to treat cancers. DÂ Three dimensional image of immunomodulatory cells (Green) and cytotoxic cells (Purple)Â which are respectively activated and inhibited by EVs (Blue)Â secreted by cancer cells (Pink)Back to article page